Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$28.26 USD
-1.40 (-4.72%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $28.27 +0.01 (0.04%) 7:58 PM ET
5-Strong Sell of 5 5
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
VRNA 28.26 -1.40(-4.72%)
Will VRNA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRNA
Verona (VRNA) Stock Surges 36% in the Past Month: Here's Why
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
VRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
Other News for VRNA
Buy Rating Affirmed for Verona Pharma Amid Strategic Partnership and Market Potential for Novel COPD Treatment
Ritedose is Proud to Partner with Verona Pharma to Deliver First-In-Class COPD Drug, Ohtuvayre (ensifentrine)*
Verona Pharma partners with Ritedose to deliver Ohtuvayre drug for COPD
Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care
Insider Sale: CFO Mark Hahn Sells 600,000 Shares of Verona Pharma PLC (VRNA)